PTC Therapeutics | PTCT - Selling And Administration Expenses


PTC Therapeutics reported $84.05M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Alnylam Pharmaceuticals USD 262.59M 60.72M Sep/2025
Amgen USD 1.7B 9M Sep/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Cytokinetics USD 158.75M 93.03M Sep/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Gilead Sciences USD 1.35B 6M Sep/2025
Incyte USD 329.08M 1.94M Sep/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Novartis USD 3.31B 134M Sep/2025
Pfizer USD 3.19B 209M Sep/2025
PTC Therapeutics USD 84.05M 1.22M Sep/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
TG Therapeutics USD 63.37M 51.33M Sep/2025
Ultragenyx Pharmaceutical USD 86.62M 26K Sep/2025
Vertex Pharmaceuticals USD 445.1M 20.5M Sep/2025
Xencor USD 87.78M 72.66M Sep/2025